Role of nitrosative stress and activation of poly(ADP-ribose) polymerase-1 in cardiovascular failure associated with septic and hemorrhagic shock

Détails

ID Serval
serval:BIB_CAA8D7D9CF1C
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Role of nitrosative stress and activation of poly(ADP-ribose) polymerase-1 in cardiovascular failure associated with septic and hemorrhagic shock
Périodique
Current Vascular Pharmacology
Auteur⸱e⸱s
Evgenov  O. V., Liaudet  L.
ISSN
1570-1611 (Print)
Statut éditorial
Publié
Date de publication
07/2005
Volume
3
Numéro
3
Pages
293-9
Notes
Journal Article
Research Support, Non-U.S. Gov't
Review --- Old month value: Jul
Résumé
Reactive oxygen and nitrogen species, particularly peroxynitrite, are potent inducers of tissue damage during systemic inflammatory response and circulatory shock. Recent evidence indicates that the toxicity of these species largely depends on their ability to trigger activation of the nuclear enzyme poly(adenosine 5'-diphosphate ribose) polymerase-1 (PARP-1). Following excessive activation, PARP-1 depletes the intracellular stores of its substrate, nicotinamide adenine dinucleotide, thus slowing glycolysis, generation of high energy phosphates, and mitochondrial electron transport. Consequently, the severe metabolic crisis induced by PARP-1 activation results in acute cell dysfunction and necrotic cell death. In addition, activation of PARP-1 plays an important role in the upregulation of inflammatory cascades via a functional association with mitogen-activated protein kinases and several transcription factors, such as nuclear factor kappa B, resulting in augmented expression of pro-inflammatory cytokines, chemokines, adhesion molecules, and enzymes. In severe sepsis and hemorrhage, PARP-1 activation has emerged as one of the central mechanisms of systemic inflammation, endothelial dysfunction, peripheral vascular failure, and reduction of cardiac contractility. Innovative therapeutic strategies based on the pharmacological inhibition of PARP-1 catalytic activity might provide benefits by preventing tissue injury, organ dysfunction, and lethality associated with these conditions.
Mots-clé
Animals Anoxia/metabolism Cardiovascular Diseases/*metabolism Enzyme Activation Enzyme Inhibitors/pharmacology Humans Inflammation Mediators/metabolism Poly(ADP-ribose) Polymerases/antagonists & inhibitors/*metabolism Reactive Nitrogen Species/metabolism Reactive Oxygen Species/metabolism Sepsis/metabolism Shock, Hemorrhagic/metabolism Signal Transduction
Pubmed
Création de la notice
24/01/2008 18:00
Dernière modification de la notice
20/08/2019 16:45
Données d'usage